1
                        SECURITIES AND EXCHANGE COMMISSION

                            WASHINGTON, D.C.  20549


                                ---------------


                                    FORM 8-K

                                 CURRENT REPORT




                     Pursuant to Section 13 or 15(d) of the
                        Securities Exchange Act of 1934



Date of Report (Date of earliest event reported) March 27, 1998
                                                 -----------------

                       BIOJECT MEDICAL TECHNOLOGIES INC.
               --------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)


                                     Oregon
                 ----------------------------------------------
                 (State or Other Jurisdiction of Incorporation)



                 0-15360                              93-1099680
         ------------------------         --------------------------------
         (Commission File Number)         (IRS Employer Identification No.)


       7620 SW Bridgeport Road
          Portland, Oregon                                            97224
- ---------------------------------------                             ----------
(Address of Principal Executive Offices)                            (Zip Code)

Registrant's telephone number, including area code  (503) 639-7221
                                                    --------------


                                     N/A
         -------------------------------------------------------------
         (Former Name or Former Address, if Changed Since Last Report)



 2

ITEM 5.  OTHER EVENTS

TEXT OF PRESS RELEASE

BIOJECT ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER

Resignation Effective April 30, 1998
_______________________________________________________________________

PORTLAND, OR - March 26, 1998 - Bioject Medical Technologies, Inc. 
(NASDAQ: BJCT), the leading manufacturer of jet injection devices for 
needle-free subcutaneous and intramuscular injections, today announced 
the resignation of Peggy Miller, the company's vice president, chief 
financial officer and secretary/treasurer.  This resignation will be 
effective April 30, 1998.  

Said Jim O'Shea, company chairman and chief executive officer, "Peggy 
has made significant contributions during the five years she has been 
with Bioject, and she has played a critical role in setting the stage 
for our further growth.  We understand her desire for new challenges 
and we wish her well."

O'Shea continued, "We have initiated a search for a new chief financial 
officer and hope to make an announcement soon."      

Bioject develops, manufactures and markets jet injection systems for 
needle-free drug delivery. The Company's advanced injection management 
system, the Biojector 2000, has received the Seal of Acceptance from 
the Alliance of Children's Hospitals, Inc. and is being marketed to 
hospitals, public health clinics, and physician offices.  The Company 
is also developing a system for Hoffmann-La Roche to market 
specifically with their products.



 3
                               SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                           BIOJECT MEDICAL TECHNOLOGIES INC.
                                          
                                          
                                          
Date:    March 27, 1998                   By /s/ Peggy J. Miller
                                           ----------------------------------
                                            Peggy J. Miller
                                            Vice President, Chief Financial
                                            Officer, Secretary/Treasurer